Novartis and Meiji Seika Sign Co-Promotion Agreement for COPD Treatments in Japan

Novartis and Meiji Seika Pharma have signed a co-promotion agreement on the Swiss company's chronic obstructive pulmonary disease (COPD) treatments Ultibro (indacaterol + glycopyrronium) and Seebri Breezhaler (glycopyrronium bromide) in Japan, according to Pharma Japan. Under the agreement, Novartis and Meiji Seika will begin co-promoting the treatments from 1 February 2016.